Studies on the interactions between C-reactive protein and complement proteins

被引:99
作者
Biro, Adrienn [1 ]
Rovo, Zita
Papp, Diana
Cervenak, Laszlo
Varga, Lilian
Fust, George
Thielens, Nicole M.
Arlaud, Gerard J.
Prohaszka, Zoltan
机构
[1] Semmelweis Univ, Dept Med 3, H-1125 Budapest, Hungary
[2] Hungarian Acad Sci, Res Grp Metab & Atherosclerosis, H-1051 Budapest, Hungary
[3] Inst Biol Struct Jean Pierre Ebel, Grenoble, France
关键词
complement; inflammation; C-reactive protein; factor H; C4b-binding protein; ACUTE MYOCARDIAL-INFARCTION; LOW-DENSITY LIPOPROTEINS; ACUTE-PHASE RESPONSE; FACTOR-H; ATHEROSCLEROTIC LESIONS; C4B-BINDING PROTEIN; INHIBITORY-ACTIVITY; HUMAN-NEUTROPHILS; INNATE IMMUNITY; ACTIVATION;
D O I
10.1111/j.1365-2567.2007.02535.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Several studies have investigated the interactions between C-reactive protein (CRP) and various complement proteins but none of them took into consideration the different structural forms of CRP. The aim of our study was to investigate whether the different antigenic forms of CRP are able to bind C1q, to trigger activation of the C1 complex and to study the ability of the various CRP forms to bind complement factor H (FH) and C4b-binding protein (C4BP). Interactions between various CRP forms and complement proteins were analysed in enzyme-linked immunosorbent assay and surface plasmon resonance tests and activation of the C1 complex was followed in a reconstituted system using purified C1q, C1r and C1s in the presence of C1-INH. Native, ligand-unbound CRP activated the classical pathway weakly. After binding to phosphocholine, native CRP bound C1q and significantly activated C1. Native CRP complexed to phosphocholine did not bind the complement regulatory proteins FH and C4BP. After disruption of the pentameric structure of CRP, as achieved by urea-treatment or by site-directed mutagenesis, C1q binding and C1 activation further increased and the ability of CRP to bind complement regulatory proteins was revealed. C1q binds to CRP through its globular head domain. The binding sites on CRP for FH and C4BP seemed to be different from that of C1q. In conclusion, in parallel with the increase in the C1-activating ability of different CRP structural variants, the affinity for complement regulatory proteins also increased, providing the biological basis for limitation of excess complement activation.
引用
收藏
页码:40 / 50
页数:11
相关论文
共 40 条
[1]   PURIFIED PROENZYME C1R - SOME CHARACTERISTICS OF ITS ACTIVATION AND SUBSEQUENT PROTEOLYTIC CLEAVAGE [J].
ARLAUD, GJ ;
VILLIERS, CL ;
CHESNE, S ;
COLOMB, MG .
BIOCHIMICA ET BIOPHYSICA ACTA, 1980, 616 (01) :116-129
[2]   DIFFERENTIAL ELUTION OF CLQ, CLR AND CLS FROM HUMAN CL BOUND TO IMMUNE AGGREGATES - USE IN THE RAPID PURIFICATION OF CL SUB-COMPONENTS [J].
ARLAUD, GJ ;
SIM, RB ;
DUPLAA, AM ;
COLOMB, MG .
MOLECULAR IMMUNOLOGY, 1979, 16 (07) :445-450
[3]   Localisation of C reactive protein in infarcted tissue sites of multiple organs during sepsis [J].
Baidoshvili, A ;
Nijmeijer, R ;
Lagrand, WK ;
Hack, CE ;
Niessen, HWM .
JOURNAL OF CLINICAL PATHOLOGY, 2002, 55 (02) :152-153
[4]   C4B-BINDING PROTEIN, A REGULATORY COMPONENT OF THE CLASSICAL PATHWAY OF COMPLEMENT, IS AN ACUTE-PHASE PROTEIN AND IS ELEVATED IN SYSTEMIC LUPUS-ERYTHEMATOSUS [J].
BARNUM, SR ;
DAHLBACK, B .
COMPLEMENT AND INFLAMMATION, 1990, 7 (02) :71-77
[5]  
BERMAN S, 1986, J IMMUNOL, V136, P1354
[6]   Modified low density lipoproteins differentially bind and activate the C1 complex of complement [J].
Biro, Adrienn ;
Thielens, Nicole M. ;
Cervenak, Laszlo ;
Prohaszka, Zoltan ;
Fust, George ;
Arlaud, Gerard J. .
MOLECULAR IMMUNOLOGY, 2007, 44 (06) :1169-1177
[7]  
CLAUS DR, 1977, J IMMUNOL, V119, P187
[8]   C-reactive protein - An activator of innate immunity and a modulator of adaptive immunity [J].
Du Clos, TW ;
Mold, C .
IMMUNOLOGIC RESEARCH, 2004, 30 (03) :261-277
[9]  
GEWURZ H, 1982, ADV INTERNAL MED, V27, P345
[10]   Multiple ligand binding sites on domain seven of human complement factor H [J].
Giannakis, E ;
Male, DA ;
Ormsby, RJ ;
Mold, C ;
Jokiranta, TS ;
Ranganathan, S ;
Gordon, DL .
INTERNATIONAL IMMUNOPHARMACOLOGY, 2001, 1 (03) :433-443